Statins are well-known for their ability to lower serum cholesterol levels, but have properties beyond mere cholesterol reduction, including an improvement in endothelial dysfunction, release of endothelial progenitor cells, anti-inflammatory properties and a number of antitumour activities. In the present issue of Clinical Science, Stumpf et al. show that a 4-week treatment course with the lipophilic statin atorvastatin ameliorates left ventricular remodelling and function, reduces serum levels of TNF-α (tumour necrosis factor-α), IL (interleukin)-6 and MCP-1 (monocyte chemoattractant protein-1), and increases both serum and myocardial levels of IL-10. The authors hypothesize that this shift from a pro- to an anti-inflammatory response might be beneficial in the clinical setting, because patients with low levels of IL-10 may fare worse than those with higher levels. In light of the recent setbacks with rosuvastatin in large-scale clinical trials, this notion requires further investigation, but highlights the need to identify those patients with heart failure who are likely to benefit from statin therapy.
Skip Nav Destination
Commentary| November 28 2008
Statins for heart failure: still caught in no man's land?
Stephan von Haehling
- Views Icon Views
- Share Icon Share
Stephan von Haehling; Statins for heart failure: still caught in no man's land?. Clin Sci (Lond) 1 January 2009; 116 (1): 37–39. doi: https://doi.org/10.1042/CS20080530
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article